Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Another radiation restenosis treatment tested :

This article was originally published in Clinica

Executive Summary

Theragenics, a US company that makes the Theraseed prostate brachytherapy device, is to test its palladium-103 technology on animal models of coronary restenosis. The Buford, Georgia-based company has signed an agreement with the Atlanta Cardiovascular Research Institute to conduct a two-phase animal study, due to begin next month. The first phase will aim to determine whether a catheter-based Pd-103 source can inhibit restenosis, while the second will test stent-based Pd-103 devices. Theragenics is the latest in a long line of companies trying to exploit the anti-restenotic properties of various types of radiation sources.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT075681

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel